Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (201-210 of 499) with videos related to

Pageof 50
Sort By:
Translational Oncology|April 17, 2016
A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular CarcinomaJeroen Dekervel, Dusan Popovic, Hannah van Malenstein, et al.
Acta Oncologica (Stockholm, Sweden)|February 11, 2020
Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of <sup>177</sup>Lu-DOTATATE PRRTEva Medaer, Chris Verslype, Eric Van Cutsem, et al.
Clinical Colorectal Cancer|July 2, 2013
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT databaseWinson Y Cheung, Qian Shi, Michael O'Connell, et al.
Journal of the National Cancer Institute|October 30, 2012
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancerArnaud D Roth, Mauro Delorenzi, Sabine Tejpar, et al.
Translational Oncology|March 8, 2020
Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic CancerAshenafi Bulle, Jeroen Dekervel, Lise Deschuttere, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 2, 2019
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancerManish A Shah, Yoon-Koo Kang, Peter C Thuss-Patience, et al.
Journal of Cancer Research and Clinical Oncology|April 13, 2018
MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approachHans-Joachim Schmoll, Dirk Arnold, Aimery de Gramont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupEric Van Cutsem, Vladimir M Moiseyenko, Sergei Tjulandin, et al.
Targeted Oncology|February 14, 2023
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid TumorsJames J Harding, Christiane Jungels, Jean-Pascal Machiels, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2025
Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trialJulien Taieb, Dominik P Modest, Marwan Fakih, et al.
Pageof 50

Showing results (201-210 of 499) with videos related to

Sort By:
Pageof 50
Translational Oncology|April 17, 2016
A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular CarcinomaJeroen Dekervel, Dusan Popovic, Hannah van Malenstein, et al.
Acta Oncologica (Stockholm, Sweden)|February 11, 2020
Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of <sup>177</sup>Lu-DOTATATE PRRTEva Medaer, Chris Verslype, Eric Van Cutsem, et al.
Clinical Colorectal Cancer|July 2, 2013
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT databaseWinson Y Cheung, Qian Shi, Michael O'Connell, et al.
Journal of the National Cancer Institute|October 30, 2012
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancerArnaud D Roth, Mauro Delorenzi, Sabine Tejpar, et al.
Translational Oncology|March 8, 2020
Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic CancerAshenafi Bulle, Jeroen Dekervel, Lise Deschuttere, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 2, 2019
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancerManish A Shah, Yoon-Koo Kang, Peter C Thuss-Patience, et al.
Journal of Cancer Research and Clinical Oncology|April 13, 2018
MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approachHans-Joachim Schmoll, Dirk Arnold, Aimery de Gramont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupEric Van Cutsem, Vladimir M Moiseyenko, Sergei Tjulandin, et al.
Targeted Oncology|February 14, 2023
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid TumorsJames J Harding, Christiane Jungels, Jean-Pascal Machiels, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2025
Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trialJulien Taieb, Dominik P Modest, Marwan Fakih, et al.
Pageof 50